Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol

By Rubenstein Marvin   Slobodskoy Leonid   Mirochnik Yelena   Guinan Patrick  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 29-35

Humana Press, Inc

Access to resources Recommend Favorite

Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 372-378

Humana Press, Inc

Access to resources Recommend Favorite

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

By Ullén Anders   Lennartsson Lena   Harmenberg Ulrika   Hjelm-Eriksson Marie   Kälkner Karl Mikael   Lennernäs Bo   Nilsson Sten  

Acta Oncologica, Vol. 44, Iss. 6, 2005-09 ,pp. : 644-650

Informa Healthcare

Access to resources Recommend Favorite

Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: Possible mechanisms?

By Ugur Ural A.   Avcu Ferit  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 491-492

Informa Healthcare

Access to resources Recommend Favorite

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 592-599

Humana Press, Inc

Access to resources Recommend Favorite